Status:

ACTIVE_NOT_RECRUITING

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

Lead Sponsor:

First Affiliated Hospital of Zhejiang University

Conditions:

Esophageal Squamous Cell Carcinoma (ESCC)

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

Esophageal squamous cell carcinoma (ESCC) is one of the malignant tumors with a high incidence worldwide, especially remaining persistently high in Asian regions. Despite advancements in early diagnos...

Eligibility Criteria

Inclusion

  • Patients with pathologically confirmed esophageal squamous cell carcinoma.
  • Clinical stage IIIB-C or IV according to the 8th edition of AJCC.
  • Having at least one measurable or evaluable lesion.
  • ECOG performance status score of 0-2.
  • Failed first-line standard treatment regimens.
  • Age ≥ 18 years.
  • Normal function of major organs.
  • Female subjects of childbearing age must undergo a pregnancy test within 3 days before the first dose with a negative result, and adopt effective contraceptive measures during the study period.

Exclusion

  • Patients with other malignant tumors requiring treatment.
  • Patients with severe diseases of major organs such as heart, liver, and kidney.
  • Patients who have previously received treatment with anti-angiogenic monoclonal antibodies or small-molecule tyrosine kinase inhibitors.
  • Patients with an expected survival period of \< 3 months.
  • Patients who have previously used fluoropyrimidine drugs (such as 5-FU, capecitabine, etc.).
  • Patients with Uncontrolled active infections (such as HIV, HCV, HBV, etc.).
  • Pregnant or lactating women.
  • Other circumstances deemed unsuitable for enrollment by the researcher.

Key Trial Info

Start Date :

August 6 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2027

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT07142421

Start Date

August 6 2025

End Date

December 30 2027

Last Update

August 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China, 310003

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma | DecenTrialz